Skip to main content
. 2018 Sep 14;19(9):2769. doi: 10.3390/ijms19092769

Figure 13.

Figure 13

Effect of GSK-3β inhibition on cell proliferation of LLC-PK1 cells treated with telocinobufagin (TCB). Serum-starved LLC-PK1 cells were treated with 10, 25, 50 and 100 nM TCB in 2.5% FBS for 72 h with or without 500 nM BIO (GSK-3β inhibitor). Trypan blue-free viable cells were counted in Neubauer chamber. Data are the mean ± SEM of at least three independent experiments in duplicate. ** p < 0.01 vs. TCB 25 nM; *** p < 0.005 vs. TCB 10 nM.